Sesen Bio, Inc. SESN
Set alert
0.63 0.00 0.00%
At close · Mar 7
0.57 Day range 0.6288
52-week range unavailable
- Open
- 0.5732
- Prev close
- 0.6288
- Mkt cap
- 127.96M
- Vol
- 1.78M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.57
- High
- 0.6288
- Forward P/E
- -1.05
- Beta
- 0.83
- Short ratio
- 2.34
- Inst. own
- 16.01%
- Dividend
- 0.00
- Ex-div date
- Mar 5, 2023
- Earnings
- Feb 28, 2023
- 50-d avg
- 0.59878
- 200-d avg
- 0.617672
- 1y target
- 12.00
2Y chart
Events in this range
- Nov 8, 2021Earnings: —; estimate -0.07; surprise —%
- Feb 28, 2022Earnings: —; estimate -0.08; surprise —%
- May 9, 2022Earnings: —; estimate -0.05; surprise —%
- Aug 8, 2022Earnings: —; estimate -0.13; surprise —%
- Nov 7, 2022Earnings: —; estimate -0.08; surprise —%
- Feb 28, 2023Earnings: —; estimate -0.11; surprise —%
- Mar 6, 2023Dividend: 0.018
Signals (74)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Mar 7, 2023 | 3 years ago |
| SMA: Bullish | Mar 7, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Mar 3, 2023 | 3 years ago |
| SMA: Bullish | Mar 3, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 3, 2023 | 3 years ago |
| SMA: Bearish | Mar 2, 2023 | 3 years ago |
| SMA: Bullish | Mar 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 27, 2023 | 3 years ago |
| SMA: Bullish | Feb 23, 2023 | 3 years ago |
| SMA: Bearish | Feb 21, 2023 | 3 years ago |
| SMA: Bearish | Feb 21, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 21, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 17, 2023 | 3 years ago |
| SMA: Bullish | Feb 14, 2023 | 3 years ago |
| SMA: Bullish | Feb 14, 2023 | 3 years ago |
| SMA: Bearish | Feb 10, 2023 | 3 years ago |
| SMA: Bullish | Feb 9, 2023 | 3 years ago |
| SMA: Bearish | Feb 8, 2023 | 3 years ago |
| SMA: Bearish | Feb 1, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 23, 2023 | 3 years ago |
| RSI: Overbought | Jan 17, 2023 | 3 years ago |
| SMA: Bullish | Dec 30, 2022 | 3 years ago |
| SMA: Bullish | Dec 30, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 30, 2022 | 3 years ago |
| RSI: Overbought | Dec 30, 2022 | 3 years ago |
| SMA: Bearish | Dec 14, 2022 | 3 years ago |
| SMA: Bullish | Dec 9, 2022 | 3 years ago |
| SMA: Bearish | Dec 8, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 22, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| SMA: Bearish | Nov 4, 2022 | 3 years ago |
| SMA: Bullish | Nov 3, 2022 | 3 years ago |
| SMA: Bearish | Nov 2, 2022 | 3 years ago |
| SMA: Bullish | Oct 31, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 5, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 21, 2022 | 4 years ago |
| RSI: Oversold | Sep 21, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 12, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 6, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 31, 2022 | 4 years ago |
| SMA: Bearish | Aug 4, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 4, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 2, 2022 | 4 years ago |
| SMA: Bullish | Jul 28, 2022 | 4 years ago |
| SMA: Bearish | Jul 22, 2022 | 4 years ago |
| SMA: Bullish | Jul 21, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 15, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 13, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 12, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 17, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 16, 2022 | 4 years ago |
| RSI: Overbought | Jun 9, 2022 | 4 years ago |
| SMA: Bullish | May 31, 2022 | 4 years ago |
| SMA: Bearish | May 6, 2022 | 4 years ago |
| SMA: Bullish | May 5, 2022 | 4 years ago |
| MACD: Buy Signal | May 3, 2022 | 4 years ago |
| RSI: Oversold | Apr 13, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 31, 2022 | 4 years ago |
| SMA: Bearish | Mar 29, 2022 | 4 years ago |
| SMA: Bullish | Mar 24, 2022 | 4 years ago |
| SMA: Bearish | Mar 23, 2022 | 4 years ago |
| SMA: Bullish | Mar 18, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 9, 2022 | 4 years ago |
| RSI: Oversold | Mar 4, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 23, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 25, 2022 | 4 years ago |
| RSI: Oversold | Jan 21, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 19, 2022 | 4 years ago |
| RSI: Oversold | Jan 19, 2022 | 4 years ago |
| MACD: Buy Signal | Dec 21, 2021 | 4 years ago |
| RSI: Oversold | Dec 3, 2021 | 4 years ago |
Key statistics
- Market cap
- 127.96M
- Enterprise value
- 2.39B
- Trailing P/E
- 0.00
- Forward P/E
- -1.05
- PEG ratio
- 0.00
- Price / sales
- 3.20
- Price / book
- 0.81
- EPS (TTM)
- -0.10
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -49.71%
- Revenue (TTM)
- 40.00M
- Revenue growth
- -100.00%
- Free cash flow
- 23.46M
- Total cash
- 166.92M
- Total debt
- 0
- Return on equity
- -12.06%
- Shares outstanding
- 203.49M
- Short % of float
- 1.05%
- 50-day average
- 0.59878
- 200-day average
- 0.617672
Analyst view
Consensus: hold
Hold
Price target (mean) 12.00
Next earnings
Feb 28, 2023
Expected Feb 28, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 28, 2023 | Dec 1, 2022 | -0.11 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.08 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.13 | — | — | — |
| May 9, 2022 | Mar 1, 2022 | -0.05 | — | — | — |
| Feb 28, 2022 | Dec 1, 2021 | -0.08 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | -0.07 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 16, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Feb 17, 2021 | Canaccord Genuity | main | — | Buy |
| Feb 17, 2021 | HC Wainwright & Co. | main | — | Buy |
| Jun 11, 2019 | H.C. Wainwright | up | Neutral | Buy |
| Jul 23, 2018 | Jefferies | init | — | Buy |
About Sesen Bio, Inc.
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sesenbio.com
News
- Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
- Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
- Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
- Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
- Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
- Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
- Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
- Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
- Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
- BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
Your note
Sign in to keep a note on SESN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOURDOW CARRIE L | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
| CANNELL THOMAS R | Chief Executive Officer | Sale | Mar 1, 2023 | 672,386 |
| DUKER JAY S | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
| FORBES MONICA | Chief Financial Officer | Sale | Mar 1, 2023 | 505,664 |
| HONIG PETER K | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
| JEWETT MICHAEL A.S. M.D. | Director | Stock Award(Grant) | Jun 21, 2022 | 40,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 5.33% | 10,854,300 | 6.83M | Dec 30, 2022 |
| Bml Capital Management, LLC | 4.04% | 8,227,969 | 5.17M | Dec 30, 2022 |
| Blackrock Inc. | 1.29% | 2,633,452 | 1.66M | Dec 30, 2022 |
| Geode Capital Management, LLC | 1.13% | 2,294,948 | 1.44M | Dec 30, 2022 |
| Millennium Management Llc | 0.51% | 1,035,151 | 650.90K | Dec 30, 2022 |
| Renaissance Technologies, LLC | 0.50% | 1,018,956 | 640.72K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.14% | 6,362,488 | 4.00M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.32% | 2,667,125 | 1.68M | Sep 29, 2022 |
| Vanguard Explorer Fund, Inc. | 0.73% | 1,476,709 | 928.55K | Oct 30, 2022 |
| Fidelity Extended Market Index Fund | 0.50% | 1,023,195 | 643.38K | Nov 29, 2022 |
| Fidelity NASDAQ Composite Index ETF | 0.22% | 438,675 | 275.84K | Dec 30, 2022 |
| Fidelity Small Cap Enhanced Index Fund | 0.15% | 304,482 | 191.46K | Nov 29, 2022 |